Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twenty-three analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one […]
More Stories
Nippon Steel Finalizes $15 Billion Takeover of US Steel
By Andrew Moran Nippon Steel and U.S. Steel announced on June 18 that they have finalized their nearly $15 billion...
Federal Reserve Keeps Interest Rates Unchanged, Signals 2 Cuts This year
By Andrew Moran The Federal Reserve kept interest rates unchanged for the fourth straight meeting on June 18, a decision...
Elon Musk’s X Sues New York Over Content-Moderation Law
By Bill Pan Elon Musk’s social media platform X is suing New York state over a new law that would...
Zero Illegal Immigrants Released Into US in May: CBP
By Naveen Athrappully Border Patrol released no illegal immigrants into the country in May, a “staggering drop” from the more...
Panthers Repeat as Stanley Cup Champions, Beat Oilers in 6 Games
By The Associated Press SUNRISE, Fla.—Stanley’s stay in South Florida is getting extended. The Florida Panthers repeated as Stanley Cup...
Karen Read’s 2nd Trial Ends With Not Guilty Verdict on Murder Charge
By Bill Pan A Massachusetts jury on Wednesday found Karen Read not guilty in the death of her boyfriend, Boston...